Autolus Therapeutics Plc (AUTL) has released an update to notify the public and investors about a regulation fd disclosure.
On February 8, 2024, a significant announcement was made regarding a new agreement between the registrant and BioNTech, details of which were released in a press statement. While this information is essential for those tracking stock market activities and company partnerships, it is not classified as filed under the Securities Exchange Act and, therefore, isn’t legally binding or liable under Section 18, nor is it part of any official filings unless explicitly stated.
For further insights into AUTL stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
